Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection)
Applicant
Vein 360
Product Code
FGB · Gastroenterology, Urology
Decision Date
Oct 20, 2026
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 876.1500
Device Class
Class 2
Attributes
Therapeutic
Indications for Use
The Vein360 Reprocessed LithoVue Digital Flexible Ureteroscopes are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
Device Story
Reprocessed single-use digital flexible ureteroscope; used for visualization and access in urinary tract. Input: CMOS imager at distal tip captures raw image data; LED provides illumination. Transformation: Raw data transmitted through handle and umbilicus to LithoVue System Workstation for processing and external display output. Operation: Physician-operated in clinical setting; enables use of accessories (baskets, laser fibers, guidewires, biopsy forceps). Benefit: Facilitates diagnostic/therapeutic procedures via transurethral/percutaneous access. Reprocessing: Includes cleaning, inspection, functional testing, and EO sterilization; devices permanently marked and tracked; limited to one reprocessing cycle.
Clinical Evidence
Bench testing only. Validation included cleaning validation (removal of artificial soil), sterilization validation (EO), biocompatibility, and performance testing (simulated use, dimensional/mechanical/electrical integrity, image quality, system compatibility). No clinical data presented.
Technological Characteristics
Flexible ureteroscope with handle and shaft. Components: LED illumination, CMOS distal imager, fiber-optic light transmission. Energy: Electrical (workstation-powered). Sterilization: Ethylene Oxide (EO) gas. Connectivity: Proprietary interface for LithoVue System Workstation. Dimensions: 3.23 mm shaft diameter, 1.15 mm instrument channel. Single-use, reprocessed once.
Indications for Use
Indicated for adolescents (12-21 years) and adults (22+ years) requiring visualization of the urinary tract (urethra, bladder, ureter, calyces, renal papillae) and diagnostic or therapeutic procedures via transurethral or percutaneous access.
Regulatory Classification
Identification
An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.
Special Controls
*Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.
In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls:
1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following:
1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures.
2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use.
3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use.
2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes.
3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches
4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error.
5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program.
(6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms.
(7) Labeling must include:
(i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified;
(ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA;
(iii) Identification of compatible devices;
(iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification;
(v) Reprocessing instructions for reusable components;
(vi) A shelf life for any sterile components;
(vii) A description of the device-specific use training program;
(viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and
(ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance.
(8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include:
(i) Device motion accuracy and repeatability;
(ii) System testing;
(iii) Instrument reliability;
(iv) Crosstalk;
(v) Table motion control;
(vi) Thermal effects on tissue;
(vii) User-device interface performance;
(viii) Workspace access testing; and
(ix) Performance testing with compatible devices.
(9) Software verification, validation, and hazard analysis must be performed.
(10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed.
(11) Performance data must demonstrate the sterility of all patient-contacting device components.
(12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life.
(13) Performance data must validate the reprocessing instructions for the reusable components of the device.
(14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible.
(15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic.
(16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information:
(i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and
(ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period.
{1}
**U.S. FOOD & DRUG**
ADMINISTRATION
October 20, 2026
Vein360
Suzanne Meyer
CEO
4460 Lake Forest Dr., Suite 218
Cincinnati, Ohio 45242
Re: K260708
Trade/Device Name: Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope
(Standard Deflection), Vein360 Reprocessed LithoVue
Digital Flexible Ureteroscope (Reverse Deflection)
Regulation Number: 21 CFR 876.1500
Regulation Name: Endoscope and accessories
Regulatory Class: II
Product Code: FGB
Dated: September 24, 2026
Received: September 24, 2026
Dear Suzanne Meyer:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: The Center for Devices and Radiological Health (CDRH) does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register.
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{2}
K260708 - Suzanne Meyer
Page 2
Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
{3}
K260708 - Suzanne Meyer
Page 3
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark R. Kreitz -S
for Mark J. Antonino, M.S.
Assistant Director
DHT3B: Division of Reproductive,
Gynecology, and Urology Devices
OHT3: Office of Gastrorenal, ObGyn,
General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{4}
K260708 - Suzanne Meyer
Page 4
The following devices are included in the scope of this 510(k) premarket notification:
| Device Name | OEM Model Numbers | Vein 360 Model Numbers | Description |
| --- | --- | --- | --- |
| Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Standard Deflection) | M0067915000 | URO-LV-STD | Reprocessed LithoVue™ Digital Flexible Ureteroscope for use with LithoVue™ System Workstation |
| Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Reverse Deflection) | M0067915100 | URO-LV-REV | Reprocessed LithoVue™ Digital Flexible Ureteroscope for use with LithoVue™ System Workstation |
{5}
| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260708 | ? |
| Please provide the device trade name(s). | | ? |
| Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection) | | |
| Please provide your Indications for Use below. | | ? |
| The Vein360 Reprocessed LithoVue Digital Flexible Ureteroscopes are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. | | |
| Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? |
| Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☑ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? |
{6}
K260708
Page 1 of 3
# Attachment17_510kSummary
**Date Prepared:** March 4, 2026
## Company Name / Contact Information
Company: Vein360, LLC
4460 Lake Forest Drive
Suite 218
Blue Ash, OH 45242
Contact: Suzanne Meyer
CEO
Phone: (513) 554-1300

## Device Name
| **Trade Names:** | Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Standard Deflection) Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Reverse Deflection) |
| --- | --- |
| **Common/Usual Name:** | Digital Flexible Ureteroscope |
| **Regulation Number** | 21 CFR 876.1500 |
| **Classification Name** | Ureteroscope and accessories, flexible/rigid |
| **Classification:** | Class II |
| **Device Product Code:** | FGB |
## Predicate Devices
For the purpose of establishing 'substantial equivalence', the design and technological characteristics of the proposed Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscopes were compared to the following 510k cleared device.
| **Trade Name:** | LithoVue™ System |
| --- | --- |
| **Common/Usual Name:** | Digital Flexible Ureteroscope |
| **Regulation Number** | 21 CFR 876.1500 |
| **Classification Name** | Ureteroscope and accessories, flexible/rigid |
| **Classification:** | Class II |
| **Device Product Code:** | FGB |
| **510k Submitter/Holder:** | Boston Scientific Corporation, Marlborough, MA |
| **510k Number/Clearance Date:** | K153049, 11/13/2015 |
## Device Description
The subject devices are reprocessed single use LithoVue™ Digital Flexible Ureteroscopes (cleared under K153049). After clinical use, the predicate devices are shipped to Vein360 following established Vein360 return instructions. Upon receipt, each device undergoes a validated reprocessing cycle that includes cleaning, inspection, functional testing, packaging and sterilization using ethylene oxide (EO) gas.
The subject devices are comprised of two main components: (1) a handle with articulation controls and accessory access ports, and (2) a flexible shaft portion. The devices are intended for use with the LithoVue™ System Workstation and are designed to allow physicians to access, visualize, and perform procedures in the urinary tract. The ureteroscopes enable delivery and use of accessory devices such as retrieval baskets, laser fibers, guidewires, and biopsy forceps.
Page 1 of 3
{7}
Attachment17_510kSummary
K260708
Page 2 of 3
The subject devices provide real-time images to the physician to facilitate diagnostic and therapeutic procedures in the urinary tract. Illumination is generated by a light emitting diode (LED) located in the digital ureteroscope handle and transmitted to the distal tip lens via a fiber-optic illumination fiber. A digital Complementary Metal-Oxide-Semiconductor (CMOS) imager located in the distal tip of the ureteroscope provides raw image data from the surgical field. The raw image data is transferred from the CMOS imager through the ureteroscope handle, via the umbilicus, to the workstation for processing and output to an external display.
Other than deflection orientation, the subject device models are identical in design, materials, and intended use to one another. Deflection is controlled by a reciprocal control mechanism within the handle body and does not affect the core functionality of the device.
As with the predicate devices, the subject devices are intended to be used exclusively with the LithoVue™ System Workstation.
Each subject device undergoes one reprocessing cycle and is permanently marked to indicate reprocessing by Vein360.
## Indications for Use
The Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscopes, reverse and standard deflection, are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
## Substantial Equivalence Information
The Vein360 reprocessed device has the same technological characteristics (i.e., design, material, chemical composition, energy source) as the predicate device. There are no changes to the intended therapeutic, diagnostic, or surgical use of the device.
The subject devices covered by the scope of this submission are substantially equivalent to the predicate devices with respect to indications for use, device design, materials, performance, and method of sterilization. As a reprocessed single use device, there are no changes to the clinical applications, patient population, or method of operation. A high-level comparison of features between the predicate and subject devices is provided below.
| Feature | Predicate Devices (K153049) | Subject Devices |
| --- | --- | --- |
| Maximum Angle of Deflection | 270 degrees (in both directions) | Same |
| Minimum Bend Radius | 8 mm | Same |
| Shaft Working Length | 68 cm | Same |
| Instrument Channel Length | 82 cm | Same |
| Maximum Insertion Portion Width (Overall Shaft Diameter) | 3.23 mm | Same |
| Minimal Instrument Channel Width | 1.15 mm | Same |
| Maximum Guidewire Outside Diameter Compatibility | 0.97 mm | Same |
| Field of View | 85° degrees in air | Same |
| Optical Working Distance | 2 - 50 mm | Same |
| Direction of View | 0° (forward viewing) | Same |
| Sterilization Method | Ethylene Oxide (EO) gas | Same |
Page 2 of 3
{8}
Attachment17_510kSummary
K260708
Page 3 of 3
| Feature | Predicate Devices (K153049) | Subject Devices |
| --- | --- | --- |
| Shelf Life | Unknown | 13 months |
| Uses | Single patient use | Same |
| Accessories | None | Same |
| Reprocessing Mark Indicator | None | Indelible mark (line) on power connector |
## Cleaning Validation
Comprehensive cleaning validation studies were performed using clinically used subject devices that were subsequently soiled with artificial test soil. The cleaning process was validated by objectively demonstrating complete removal of physical soil under the defined minimum operating conditions. Supporting data for the cleaning process and its validation are included in this submission.
## Performance Validation
Performance validation studies were performed after ensuring subject devices were clinically used and then soiled with artificial test soils. The cleaning process was performed under conditions intentionally selected to impose the greatest potential stress on the devices, including the longest exposure times and highest chemical concentrations, in order to maximally challenge device functional performance. Electro-mechanical performance testing was performed to demonstrate that the reprocessing operations did not adversely affect the predicate device's form, fit, or function.
Bench and laboratory testing included:
- Cleaning Validation
- Sterilization Validation
- Biocompatibility
- Performance Validation
- Simulated Use
- Dimensional Integrity
- Mechanical integrity
- Image Quality
- Electrical Integrity
- Electrical Safety
- System Compatibility
- Packaging Validation
Performance testing demonstrated that the subject devices are substantially equivalent to the predicate device for their intended use. The subject devices were validated for one reprocessing cycle following completion of performance testing.
The subject devices are permanently marked and tracked using unique serial numbers applied by Vein360 during the reprocessing cycle. Devices are removed from service and excluded from further reprocessing once they reach the maximum allowable number of reprocessing cycles. In addition, Vein360 limits reprocessing exclusively to devices with no prior reprocessing history and does not accept devices previously reprocessed by other reprocessors.
## Conclusion
Vein360 concludes the subject devices are as safe, as effective, and perform as well as the predicate devices.
Page 3 of 3
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Guidance alerts
New and changed FDA guidance documents, emailed as a daily digest.
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the ? button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only Software as a Medical Device, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (Software as a Medical Device), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.